Literature DB >> 1873852

Cell adhesion receptor expression during melanoma progression and metastasis.

I R Hart1, M Birch, J F Marshall.   

Abstract

Many steps in melanoma metastasis involve cell-cell or cell-matrix adhesive interactions. The surface molecules which mediate these processes therefore play an important role in regulating melanoma dissemination and their level of expression may alter during the course of tumor progression. Human melanocyte strains and melanoma cell lines have been characterised with regard to levels of cell surface receptors of the integrin family. Increased amounts of at least two integrins, VLA-4 (alpha 4 beta 1) and VnR (alpha v beta 3), appeared to correlate with progression in this tumor, type. A novel VnR composed of an alpha v beta 1 association has been observed in one melanoma cell line and there is the possibility that heterogeneity of integrin composition could affect biological behavior of these tumors. CD44, a cell surface glycoprotein which functions as the major receptor for hyaluronate, is another molecule whose expression increases in transformed cells of the melanocytic lineage. Iterative sorting on the FACS for stable variants, of both human and murine melanomas, expressing low and high levels of CD44 established that lack of expression of this molecule correlated with impaired ability to form pulmonary tumor nodules subsequent to i.v. injection into appropriate recipient mice. These findings illustrate that an understanding of the regulation of melanoma adhesion receptors could provide insights into the process of tumor spread.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873852     DOI: 10.1007/bf00049409

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  113 in total

1.  Changes in integrin receptors on oncogenically transformed cells.

Authors:  L C Plantefaber; R O Hynes
Journal:  Cell       Date:  1989-01-27       Impact factor: 41.582

Review 2.  VLA proteins in the integrin family: structures, functions, and their role on leukocytes.

Authors:  M E Hemler
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

3.  Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells.

Authors:  F G Giancotti; E Ruoslahti
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

Review 4.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

Review 5.  The migration and differentiation of neural crest cells.

Authors:  J A Weston
Journal:  Adv Morphog       Date:  1970

6.  Monoclonal antibody to a human brain-granulocyte-T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat.

Authors:  R Dalchau; J Kirkley; J W Fabre
Journal:  Eur J Immunol       Date:  1980-10       Impact factor: 5.532

7.  An inducible endothelial cell surface glycoprotein mediates melanoma adhesion.

Authors:  G E Rice; M P Bevilacqua
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

8.  The distribution and spatial organization of the extracellular matrix encountered by mesencephalic neural crest cells.

Authors:  P R Brauer; D L Bolender; R R Markwald
Journal:  Anat Rec       Date:  1985-01

9.  Peyer's patch-specific lymphocyte homing receptors consist of a VLA-4-like alpha chain associated with either of two integrin beta chains, one of which is novel.

Authors:  B Holzmann; I L Weissman
Journal:  EMBO J       Date:  1989-06       Impact factor: 11.598

10.  Binding of hyaluronate to the surface of cultured cells.

Authors:  C B Underhill; B P Toole
Journal:  J Cell Biol       Date:  1979-08       Impact factor: 10.539

View more
  32 in total

1.  Elucidation of a common structure of selective fibrinogen receptor antagonists.

Authors:  H Minoux; N Moitessier; Y Chapleur; B Maigret
Journal:  J Comput Aided Mol Des       Date:  1998-11       Impact factor: 3.686

Review 2.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

3.  PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.

Authors:  Wissam Beaino; Carolyn J Anderson
Journal:  J Nucl Med       Date:  2014-09-25       Impact factor: 10.057

4.  Serum levels of the soluble adhesion molecules in patients with malignant melanoma.

Authors:  V Yasasever; F Tas; D Duranyildiz; H Camlica; S Kurul; N Dalay
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 5.  Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions.

Authors:  T W Kuijpers
Journal:  Springer Semin Immunopathol       Date:  1995

Review 6.  Invasion promoter versus invasion suppressor molecules: the paradigm of E-cadherin.

Authors:  M Mareel; M Bracke; F Van Roy
Journal:  Mol Biol Rep       Date:  1994-01       Impact factor: 2.316

Review 7.  Are cellular adhesion molecules involved in the metastasis of breast cancer?

Authors:  M Maemura; R B Dickson
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.

Authors:  Wissam Beaino; Jessie R Nedrow; Carolyn J Anderson
Journal:  Mol Pharm       Date:  2015-05-08       Impact factor: 4.939

9.  Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA.

Authors:  J L Herrmann; D G Menter; J Hamada; D Marchetti; M Nakajima; G L Nicolson
Journal:  Mol Biol Cell       Date:  1993-11       Impact factor: 4.138

10.  Expression and ligand-binding function of the integrin alpha 4 beta 1 (VLA-4) on neural-crest-derived tumor cell lines.

Authors:  J L Bednarczyk; B W McIntyre
Journal:  Clin Exp Metastasis       Date:  1992-07       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.